Contents to Volumes 1, 2, and 3

Volume 1

Part I Methodological and Technological Advances

1 Where Do We Stand in the Quest for Neuropsychiatric Biomarkers and Endophenotypes and What Next?
Michael S. Ritsner and Irving I. Gottesman

2 Methodological and Statistical Issues in the Use of Biomarkers in Clinical and Research Studies
Ryan J. Van Lieshout and Peter Szatmari

3 Challenging the Genetic Complexity of Schizophrenia by Use of Intermediate Phenotypes
Assen Jablensky

Georg Winterer

5 Leveraging High-Dimensional Neuroimaging Data in Genetic Studies of Neuropsychiatric Disease
Cinnamon S. Bloss, Trygve E. Bakken, Alexander H. Joyner, and Nicholas J. Schork

6 Proteomics as a New Tool for Biomarker-Discovery in Neuropsychiatric Disorders
Thomas J. Raedler, Harald Mischak, Holger Jahn, and Klaus Wiedemann

7 Schizophrenia Endophenotypes as Treatment Targets
Part II  Neuropsychological, Neurocognitive and Neurophysiological Domains

8 Neuropsychological Endophenotypes in Schizophrenia and Bipolar I Disorder: Yields from the Finnish Family and Twin Studies
   Annamari Tuulio-Henriksson, Jonna Perälä, Irving I. Gottesman, and Jaana Suvisaari

9 Is More Cognitive Experimental Psychopathology of Schizophrenia Really Necessary? Challenges and Opportunities
   Angus W. MacDonald, III

10 Intellectual Functioning as an Endophenotype for Schizophrenia
    Odette de Wilde

11 Emotion Recognition Deficits as a Neurocognitive Marker of Schizophrenia Liability
    Renata Schoeman, Dana J.H. Niehaus, Liezl Koen, and Jukka M. Leppänen

12 The Use of Neurocognitive Endophenotypes in Large-Scale Family Genetic Studies of Schizophrenia
    William P. Horan, Tiffany A. Greenwood, David L. Braff, Raquel E. Gur, and Michael F. Green

13 Neurocognitive Endophenotypes for Bipolar Disorder: Evidence from Case-Control, Family and Twin Studies
    Eugenia Kravariti, Fergus Kane, and Robin M. Murray

14 Trait and State Markers of Schizophrenia in Visual Processing
    Yue Chen, Daniel Norton, and Ryan McBain

15 Visual Scanning Abnormalities as Biomarker for Schizophrenia
    Patricia E.G. Bestelmeyer

16 Biomarkers and Endophenotypes in Eating Disorders
    Carolina Lopez, Marion Roberts, and Janet Treasure

17 Movement Abnormalities: A Putative Biomarker of Risk for Psychosis
    Vijay A. Mittal and Elaine F. Walker

Contents to Volumes 2, 3, and 4

Contributors to Volumes 2, 3, and 4

Index
Volume 2

Part III Neuroanatomical and Neuroimaging Findings

18 Neuroimaging Biomarkers in Alzheimer’s Disease
Chong Mei Sian and Lim Wee Shiong

19 Role of Imaging Techniques in Discerning Neurobehavioral Changes in Ischemic, Neurodegenerative and Demyelinating Disorders
Turi O. Dalaker, Mona K. Beyer, Milena Stosic, and Robert Zivadinov

20 Towards a Functional Neuroanatomy of Symptoms and Cognitive Deficits of Schizophrenia
David Linden

21 Functional and Structural Endophenotypes in Schizophrenia
Stephan Bender, Matthias Weisbrod, and Franz Resch

22 Neuromorphometric Measures as Endophenotypes of Schizophrenia Spectrum Disorders
Daniel Mamah, Deanna M. Barch, and John G. Csernansky

23 Magnetic Resonance Imaging Biomarkers in Schizophrenia Research
Heike Tost, Shabnam Hakimi, and Andreas Meyer-Lindenberg

24 Neurostructural Endophenotypes In Autism Spectrum Disorder
Armin Raznahan, Jay N Giedd, and Patrick F Bolton

25 Neuroimaging Biomarkers for Bipolar Disorder Across the Lifespan
Nick C. Patel, Michael A. Cerullo, David E. Fleck, Jayasree J. Nandagopal, Caleb M. Adler, Stephen M. Strakowski, and Melissa P. DelBello

26 Neuroimaging Studies of Pediatric Obsessive-Compulsive Disorder: Special Emphasis on Genetics and Biomarkers
Frank P. MacMaster and David R. Rosenberg

27 Structural Brain Alterations in Cannabis Users: Association with Cognitive Deficits and Psychiatric Symptoms
Nadia Solowij, Murat Yücel, Valentina Lorenzetti, and Dan I. Lubman

Contents to Volumes 1, 3, and 4

Contributors to Volumes 1, 3, and 4

Index
Volume 3

Part IV Possible Metabolic and Peripheral Biomarkers

28 Peripheral Biomarkers in Dementia and Alzheimer’s Disease
   Christian Humpel and Josef Marksteiner

29 S100B as a Potential Neurochemical Biomarker in a Variety of Neurological, Neuropsychiatric and Neurosurgical Disorders
   Patrick Wainwright, Jon Sen, and Antonio Belli

30 Can the Cortisol to DHEA Molar Ratio be Used as a Peripheral Biomarker for Schizophrenia and Mood Disorders?
   Peter Gallagher and Michael S. Ritsner

31 Neuroactive Steroid Biomarkers of Alcohol Sensitivity and Alcoholism Risk
   A. Leslie Morrow and Patrizia Porcu

32 Neuroendocrine Markers of Psychopathy
   Andrea L. Glenn

33 Mitochondrial Complex I as a Possible Novel Peripheral Biomarker for Schizophrenia
   Dorit Ben-Shachar

34 Peripheral Biomarkers of Excitotoxicity in Neurological Diseases
   Lucio Tremolizzo, Gessica Sala, and Carlo Ferrarese

35 Melatonin as a Biological Marker in Schizophrenia
   Armando L. Morera, Pedro Abreu-Gonzalez, and Manuel Henry

36 Peripheral Biological Markers for Mood Disorders
   Ghanshyam N. Pandey and Yogesh Dwivedi

37 The Diagnosis of Alcoholism Through the Identification of Biochemical Markers in Hair
   Nadia De Giovanni

38 Retinoic Acid Signalling in Neuropsychiatric Disease: Possible Markers and Treatment Agents
   Sarah J. Bailey and Peter J. McCaffery

39 Abnormalities of Inositol Metabolism in Lymphocytes as Biomarkers for Bipolar Disorder
   Galila Agam, Yuly Bersudsky, and Robert H. Belmaker

Contents to Volumes 1, 2, and 3

Contributors to Volumes 1, 2, and 4

Index
Contributors to Volumes 1, 2 and 3

Volume 1

**Trygve E. Bakken**  M.Sc., Scripps Genomic Medicine and Scripps Translational Science Institute; Medical Scientist Training Program and Graduate Program in Neurosciences, University of California, San Diego, CA, USA
E-mail: tbaakken@ucsd.edu

**Patricia E.G. Bestelmeyer**, Ph.D., Post-Doc Centre for Cognitive Neuroimaging Department of Psychology, Glasgow, UK
E-mail: p.bestelmeyer@psy.gla.ac.uk

**Cinnamon S. Bloss**, Ph.D., Research Scientist, Scripps Genomic Medicine and Scripps Translational Science Institute, Scripps Health and The Scripps Research Institute, La Jolla, CA, USA
E-mail: cbloss@scripps.edu

**David L. Braff**, M.D., Professor, Department of Psychiatry, University of California, San Diego, CA, USA
E-mail: DBraff@ucsd.edu

**Jessica A. Burket**, B.S., Mental Health Service Line, Department of Veterans Affairs Medical Center, Washington, USA

**Yue Chen**, Ph.D., Director, Visual Psychophysiology Laboratory, McLean Hospital, Department of Psychiatry, Harvard Medical School, Belmont, MA, USA
E-mail: ychen@mclean.harvard.edu

**Stephen I. Deutsch**, M.D., Ph.D., Mental Health Service Line, Department of Veterans Affairs Medical Center, Washington, Department of Psychiatry, Georgetown University School of Medicine, Washington, USA
E-mail: Stephen.Deutsch@va.gov

**Ayman H. Fanous**, M.D., Mental Health Service Line, Department of Veterans Affairs Medical Center, Washington, Department of Psychiatry, Georgetown University School of Medicine, Washington, USA

**Brooke L. Gaskins**, B.A., Mental Health Service Line, Department of Veterans Affairs Medical Center, Washington, USA
Irving I. Gottesman  Professor, Departments of Psychiatry and Psychology, University of Minnesota, Minneapolis, MN, USA
E-mail: gotte003@umn.edu

Michael F. Green, Ph.D., Professor, Semel Institute, University of California, Los Angeles, CA, USA
E-mail: mgreen@ucla.edu

Tiffany A. Greenwood, Ph.D., Assistant Adjunct Professor of Psychiatry, Department of Psychiatry, University of California, San Diego, CA, USA
E-mail: tgreenwood@ucsd.edu

Raquel E. Gur, M.D., Ph.D., The Karl and Linda Rickels Professor and Vice Chair for Research Development, Departments of Psychiatry, Neurology and Radiology, Director, Neuropsychiatry Section, University of Pennsylvania Medical Center, Philadelphia, PA, USA
E-mail: raquel@upenn.edu

William P. Horan, Ph.D., VA Greater Los Angeles Healthcare system & University of California, Los Angeles, CA, USA
E-mail: horan@ucla.edu

Assen Jablensky, M.D., D. Med.Sci., Professor of Psychiatry, School of Psychiatry and Clinical Neurosciences, The University of Western Australia, Director, Centre for Clinical Research in Neuropsychiatry, Australia
E-mail: assen@cyllene.uwa.edu.au

Holger Jahn  University of Hamburg, Department of Psychiatry, Hamburg, Germany

Alexander H. Joyner  M.Eng., Scripps Genomic Medicine and Scripps Translational Science Institute; Graduate Program in Biomedical Sciences, University of California, San Diego, CA, USA
E-mail: ajoyner@ucsd.edu

Fergus Kane, Ph.D. student at the section of General Psychiatry, Department of Psychiatry, Institute of Psychiatry, London, UK

Liezl Koen, M.B. Ch.B., M.Med. (Psych), Department of Psychiatry, University of Stellenbosch, South Africa
E-mail: liezlk@sun.ac.za

Eugenia Kravariti, M.A., M.Sc., Ph.D., Lecturer, NIHR Biomedical Research Centre for Mental Health, South London and Maudsley NHS Foundation Trust and Institute of Psychiatry, King’s College London, UK
E-mail: e.kravariti@iop.kcl.ac.uk

Jukka M. Leppänen, Ph.D., Assistant Professor, Department of Psychology, University of Tempere, Tempere, Finland
E-mail: jukka.leppanen@ufa.fi

Ryan J. Van Lieshout  The Offord Centre for Child Studies, McMaster Children’s Hospital and Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada
E-mail: rjv@prontomail.com
Carolina Lopez  Eating Disorders Research Unit, Department of Academic Psychiatry, King’s College London, UK
E-mail: c.lopez@iop.kcl.ac.uk

Angus W. MacDonald, III, Ph.D., Associate Professor, Departments of Psychology and Psychiatry, University of Minnesota, Minneapolis, Minnesota, USA
E-mail: angus@umn.edu

John Mastropaolo, Ph.D. Mental Health Service Line, Department of Veterans Affairs Medical Center, Washington, USA

Ryan McBain  McLean Hospital, Belmont, MA, USA

Harald Mischak  Mosaiques Diagnostics and Therapeutics AG, Hannover, Germany

Vijay A. Mittal, Ph.D., Postdoctoral Scholar, Department of Psychology, University of California Los Angeles, USA
E-mail: vmittal@mednet.ucla.edu

Robin M. Murray, Professor of Psychiatry, Institute of Psychiatry, King’s College London, UK
E-mail: robin.murray@iop.kcl.ac.uk

Dana J.H. Niehaus, M.B. Ch.B., M.Med. (Psych.), D.Med. (Psych.), FC Psych., Department of Psychiatry, University of Stellenbosch, South Africa
E-mail: djhn@sun.ac.za

Daniel Norton  McLean Hospital, Belmont, MA, USA

Jonna Perälä, M.D., Researcher, National Public Health Institute, Department of Mental Health and Alcohol Research, Helsinki, Finland
E-mail: jonna.perala@ktl.fi

Thomas J. Raedler, M.D., Associate Professor, Department of Psychiatry, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
E-mail: Thomas.Raedler@albertahealthservices.ca; Thomas.Raedler@Calgaryhealthregion.ca

Michael S. Ritsner, M.D., Ph.D., Associate Professor of Psychiatry and Head of Cognitive and Psychobiology Research Laboratory, The Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa and Chair, Acute Department, Sha’ar Menashe Mental Health Center, Hadera, Israel
E-mail: ritsner@sm.health.gov.il

Marion Roberts, Eating Disorders Research Unit, Department of Academic Psychiatry, Institute of Psychiatry, King’s College London, 5th Floor Bermondsey Wing, Guy’s Hospital, London, SE1 9RT ddi. 0207 188 0181
E-mail: marion.roberts@iop.kcl.ac.uk; www.eatingresearch.com

Richard B. Rosse, M.D., Mental Health Service Line, Department of Veterans Affairs Medical Center, Washington, Department of Psychiatry, Georgetown University School of Medicine, Washington, USA

Renata Schoeman, M.B. Ch.B., M.Soc. Sc., M.Med. (Psych.), FC Psych., Department of Psychiatry, University of Stellenbosch, South Africa
E-mail: bibitica@mweb.co.za
Contributors to Volumes 1, 2, and 3

Nicholas J. Schork, Ph.D., Director of Research, Scripps Genomic Medicine; Director of Biostatistics and Bioinformatics, The Scripps Translational Science Institute; Professor, Molecular and Experimental Medicine, Scripps Health and The Scripps Research Institute, CA, USA
E-mail: nschork@scripps.edu

Barbara L. Schwartz, Ph.D., Mental Health Service Line, Department of Veterans Affairs Medical Center, Washington, Department of Psychiatry, Georgetown University School of Medicine, Washington, USA

Jaana Suvisaari, M.D., Ph.D., Academy research fellow, National Public Health Institute Department of Mental Health and Alcohol Research, Helsinki, Finland
E-mail: jaana.suvisaari@ktl.fi

Peter Szatmari Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada
E-mail: szatmar@mcmaster.ca

Janet Treasure Psychological Medicine Department, King’s College London, Institute of Psychiatry, London, UK
E-mail: Janet.Treasure@iop.kcl.ac.uk

Annamari Tuulio-Henriksson, Ph.D., Senior Researcher, National Public Health Institute Department of Mental Health and Alcohol Research, Helsinki, Finland
E-mail: annamari.tuulio-henriksson@ktl.fi

Elaine F. Walker, Ph.D., Samuel Candler Dobbs Professor of Psychology and Neuroscience, Department of Psychology, Emory University, USA
E-mail: psyefw@emory.edu

Abraham Weizman, M.D., Professor of Psychiatry, Research Unit, Geha Mental Health Center and the Laboratory of Biological Psychiatry at Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Tel-Aviv
E-mail: Israel. aweizman@clalit.org.il

Klaus Wiedemann University of Hamburg, Department of Psychiatry, Hamburg, Germany

Odette de Wilde, Ph.D., Academic Medical Center, University of Amsterdam, Department of Psychiatry, The Netherlands
E-mail: o.dewilde@amc.uva.nl

Georg Winterer, M.D., Ph.D., Associate Professor, Department of Psychiatry, Heinrich-Heine University, Duesseldorf, and Institute of Neurosciences and Biophysics, Juelich Research Centre, Juelich, Germany
E-mail: georg.winterer@uni-duesseldorf.de

Volume 2

Caleb M. Adler, M.D., Associate Professor of Psychiatry, Co-Director, Division of Bipolar Disorders Research, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH, USA
E-mail: adlercb@uc.edu
Deanna M. Barch, Ph.D., Professor, Departments of Psychology, Psychiatry and Radiology, Washington University, St. Louis, MO, USA
E-mail: dbarch@wustl.edu

Stephan Bender  Senior scientist and commissionary Head of the joint Neurophysiological Laboratory of the Psychiatric, Psychosomatic and Child and Adolescent Psychiatric Hospital of the University of Heidelberg, Germany
E-mail: Stephan.Bender@med.uni-heidelberg.de

Mona K. Beyer, M.D., Ph.D., Department of Radiology, Stavanger University Hospital, Stavanger, Norway; The Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway

Michael A. Cerullo, M.D., Assistant Professor of Psychiatry, Division of Bipolar Disorders Research, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH, USA
E-mail: michael.cerullo@uc.edu

John G. Csernansky, M.D., Lizzie Gilman Professor and Chairman, Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
E-mail: igc@northwestern.edu

Turi O. Dalaker, M.D., Buffalo Neuroimaging Analysis Center, Department of Neurology, State University of New York at Buffalo, Buffalo, NY, USA; Department of Radiology, Stavanger University Hospital, Stavanger, Norway; The Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway
E-mail: datu@sus.no

Melissa P. DelBello, M.D., M.S., Vice-Chair for Clinical Research, Department of Psychiatry; Associate Professor of Psychiatry and Pediatrics, Division of Bipolar Disorders Research, University of Cincinnati College of Medicine, Cincinnati, OH, USA
E-mail: delbelmp@email.uc.edu

David E. Fleck, Ph.D., Assistant Professor of Psychiatry, Division of Bipolar Disorders Research, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH, USA
E-mail: david.fleck@uc.edu

Shabnam Hakimi, B.A., Clinical Brain Disorders Branch, Genes, Cognition, and Psychosis Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA

David Linden  Professor of Biological Psychiatry, Wales Institute of Cognitive Neuroscience and North Wales Clinical School, School of Psychology, University of Wales Bangor, Bangor, UK
E-mail: d.linden@bangor.ac.uk

Valentina Lorenzetti  Ph.D. candidate, Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Australia
E-mail: vlor@unimelb.edu.au
Dan I. Lubman, Ph.D., FRANZCP, FAcHAM; Associate Professor, ORYGEN Research Centre, Department of Psychiatry, University of Melbourne, Victoria, Australia
E-mail: dan.lubman@mh.org.au

Frank P. MacMaster, Ph.D., Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine Detroit, MI, USA
E-mail: fmacmast@med.wayne.edu

Daniel Mamah, M.D., M.P.E., Instructor, Department of psychiatry, Washington University School of Medicine St. Louis; President, Eastern Missouri Psychiatric Society, USA
E-mail: mamahd@psychiatry.wustl.edu

Chong Mei Sian  Consultant, Department of Geriatric Medicine, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore
E-mail: Mei_Sian_Chong@ttsh.com.sg

Andreas Meyer-Lindenberg, M.D., Ph.D., Director of the Central Institute of Mental Health, Professor of Psychiatry and Psychotherapy, Faculty of Clinical Medicine Mannheim, University of Heidelberg, Germany
E-mail: a.meyer-lindenberg@zi-mannheim.de

Jayasree J. Nandagopal, MD, Assistant Professor of Psychiatry, Division of Bipolar Disorders Research, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH, USA
E-mail: jayasree.nandagopal@uc.edu

Nick C. Patel, Pharm.D., Ph.D., Clinical Pharmacist, Lifesynch; and Clinical Assistant Professor & Health Behavior, Medical College of Georgia; USA
E-mail: npatel5@lifesynch.com

Armin Raznahan, MBBS, MRCPCH, MRCPych., Medical Research Council Clinical Research Training Fellow, Institute of Psychiatry, King’s College London, UK
E-mail: Armin.Raznahan@iop.kcl.ac.uk

Franz Resch  Professor, Director of the Child and Adolescent Psychiatric Hospital of the University of Heidelberg, Germany
E-mail: Franz.Resch@med.uni-heidelberg.de

David R. Rosenberg, M.D., Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Children’s Hospital of Michigan, Detroit, MI, USA
E-mail: drosen@med.wayne.edu

Lim Wee Shiong  Consultant, Department of Geriatric Medicine, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore

Nadia Solowij, Ph.D., Senior Lecturer, School of Psychology and Illawarra Institute for Mental Health, University of Wollongong, Australia, Affiliated Scientist, Schizophrenia Research Institute, Sydney, Australia
E-mail: nadia@uow.edu.au
Contributors to Volumes 1, 2, and 3

**Milena Stosic**, M.D., Buffalo Neuroimaging Analysis Center, Department of Neurology, State University of New York at Buffalo, Buffalo, NY, USA

**Stephen M. Strakowski**, MD, The Stanley and Mickey Kaplan Professor and Chair of Psychiatry Professor of Psychology and Biomedical Engineering Director, Center for Imaging Research University of Cincinnati College of Medicine, Cincinnati, OH, USA
E-mail: stephen.strakowski@uc.edu

**Heike Tost**, M.D., Ph.D., Post-Doctoral Research Fellow, Clinical Brain Disorders Branch, Genes, Cognition, and Psychosis Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
E-mail: tosth@mail.nih.gov

**Matthias Weisbrod**, Professor, Director of the SRH Psychiatric Hospital Karlsbad-Langensteinbach; Head of the Section for Experimental Psychopathology of the University of Heidelberg, Germany
E-mail: Matthias.Weisbrod@kkl.srh.de

**Murat Yücel**, Ph.D., MAPS; Senior Lecturer and Clinical Neuropsychologist, Melbourne Neuropsychiatry Centre and ORYGEN Research Centre, Department of Psychiatry, University of Melbourne and Melbourne Health, National Neuroscience Facility, Melbourne, Australia
E-mail: murat@unimelb.edu.au

**Robert Zivadinov**, M.D., Ph.D., Buffalo Neuroimaging Analysis Center, Department of Neurology, State University of New York at Buffalo, Buffalo, NY, USA
E-mail: rzivadinov@bnac.net

Volume 3

**Pedro Abreu-Gonzalez** Professor of Biochemistry, Department of Physiology, School of Medicine, University of La Laguna, La Laguna, Santa Cruz de Tenerife, Canary Islands, Spain

**Galila Agam**, Ph.D., Associate Professor, Psychiatry Research Unit and Department of Clinical Biochemistry, Faculty of Medicine, Ben Gurion University, Israel

**Sarah J. Bailey** Lecturer, Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, UK
E-mail: S.Bailey@bath.ac.uk

**Dorit Ben-Shachar**, Ph.D., Head of Lab, Laboratory of Psychobiology, Department of psychiatry, B. Rappaport Faculty of Medicine, Rambam Medical Center, Technion IIT, Haifa, Israel
E-mail: shachar@tx.technion.ac.il

**Yuly Bersudsky**, M.D., Ph.D., Senior Lecturer, Faculty of Medicine, Ben Gurion University, Beersheva Mental Health Center, Beersheva, Israel
Yogesh Dwivedi, Ph.D., Associate Professor, University of Illinois at Chicago, Department of Psychiatry, Chicago, IL, USA
E-mail: ydwivedi@psych.uic.edu

Carlo Ferrarese, M.D., Ph.D., Professor of Neurology, Director of the Department of Neurology and of the Neurology Residency School, University of Milano-Bicocca, Ospedale San Gerardo, Monza, Italy
E-mail: carlo.ferrarese@unimib.it

Peter Gallagher Research Associate in Psychiatry, School of Neurology, Neurobiology and Psychiatry, Newcastle University, Leazes Wing (Psychiatry), Newcastle upon Tyne, UK
E-mail: peter.gallagher@ncl.ac.uk

Nadia De Giovanni Istituto Medicina Legale, Università Cattolica S. Cuore, Roma, Italy
E-mail: nadia.degiovanni@rm.unicatt.it

Andrea L. Glenn, M.A., Doctoral Student, University of Pennsylvania, Philadelphia, PA, USA
E-mail: aglenn@sas.upenn.edu

Manuel Henry Professor of Psychiatry, Department of Internal Medicine, Dermatology and Psychiatry, School of Medicine, University of La Laguna, La Laguna, Santa Cruz de Tenerife, Canary Islands, Spain

Christian Humpel Associate Professor Dr., Laboratory of Psychiatry and Exp. Alzheimer’s Research, Department of General Psychiatry, Innsbruck Medical University, Innsbruck, Austria
E-mail: christian.humpel@i-med.ac.at

Josef Marksteiner, M.D., Associate Professor Dr., Laboratory of Psychiatry and Exp. Alzheimer’s Research, Department of General Psychiatry, Innsbruck Medical University, Innsbruck, Austria
E-mail: J.Marksteiner@i-med.ac.at

Peter McCaffery Professor, University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen, UK
E-mail: p.j.mccaffery@abdn.ac.uk

Armando L. Morera Professor of Psychiatry, Department of Internal Medicine, Dermatology and Psychiatry, School of Medicine, University of La Laguna, La Laguna, Santa Cruz de Tenerife, Canary Islands, Spain
E-mail: amorera@ull.es

A. Leslie Morrow, Ph.D., Professor of Psychiatry and Pharmacology, Associate Director, Bowles Center for Alcohol Studies, University of North Carolina School of Medicine, USA
E-mail: morrow@med.unc.edu

Ghanshyam N. Pandey, Ph.D., Professor, University of Illinois at Chicago, Department of Psychiatry, Chicago, IL, USA
E-mail: gpandey@psych.uic.edu
Contributors to Volumes 1, 2, and 3

**Patrizia Porcu**  Assistant Professor of Psychiatry, Bowles Center for Alcohol Studies, University of North Carolina School of Medicine, USA
E-mail: patrizia_porcu@med.unc.edu

**Michael S. Ritsner, M.D., Ph.D.,**  Associate Professor of Psychiatry and Head of Cognitive and Psychobiology Research Laboratory, The Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa and Chair, Acute Department, Sha’ar Menashe Mental Health Center, Hadera, Israel
E-mail: ritsner@sm.health.gov.il

**Gessica Sala, Ph.D.,**  Post-doctoral Research Associate, Department of Neuroscience and Biomedical Technologies, University of Milano-Bicocca, Italy
E-mail: gessica.sala@unimib.it

**Jon Sen**  Specialty Registrar in Neurosurgery; Wessex Neurological Centre, Southampton University Hospitals, UK
E-mail: jsen@ion.ucl.ac.uk

**Lucio Tremolizzo, M.D., Ph.D.,**  Neurologist and Post-doctoral Research Associate, University of Milano-Bicocca; Ospedale San Gerardo, Monza, Italy
E-mail: lucio.tremolizzo@unimib.it
Index

A
Adenine triphosphate (ATP), 50, 65, 67, 69, 131
Addiction, 13, 37, 38, 50, 183–190, 206
Adrenergic receptors, 3, 10, 35, 48
Adverse drug reaction (ADRs), 3, 4, 42, 47, 57, 65–73
Alcohol dependence, 9, 10, 13, 205
Alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptors, 95, 106, 156
Alzheimer’s disease, 3–8, 11, 12, 16–20, 22, 23, 42–46, 51–56, 68, 143, 199, 211
Amyotrophic lateral sclerosis (ALS), 50
Anorexia nervosa, 9, 10, 110, 184
Antiepileptic drugs, 65, 69–71, 73, 140, 151, 152
Apolipoprotein E (APOE), 3, 5, 6, 8, 15–19, 35, 42, 43, 48, 51–56, 65, 68, 131
Apoptosis, 12, 15, 18, 51, 52, 154, 199, 200, 204
Attention, 10, 81, 101, 105, 106, 111–113, 167, 177, 198, 205, 206
Attentional Deficit Hyperactive Disorder (ADHD), 135, 136, 173, 174, 178, 206
Autism, 111, 136, 143, 176, 178

B
Brain Derived Neurotrophic Factor (BDNF), 10, 51, 77, 83, 84, 99, 126–132, 178
Brain injuries, 13, 152
Brief Psychiatric Rating Scale (BPRS), 96, 101–104

C
Calcineurin (PPP3CC), 99, 100, 113, 114
Central nervous system (CNS), 3–5, 12–14, 20, 21, 24, 41, 42, 47–51, 56, 57, 67, 95, 99–101, 106, 109, 113, 129, 131, 144, 177, 179, 199, 201, 205, 206
Cerebral spinal fluid (CSF), 70
Cholesterol, 6, 7, 13, 15, 43–45, 49, 51, 52, 196–199
Cingulate Gyrus (CG), 71, 88, 102, 177
Cognition, 14, 15, 21, 46, 53, 54, 96, 105, 106, 189, 195, 197, 201
Cognitive behavior therapy (CBT), 173
Cognitive endophenotypes, 213
Corticotrophin-releasing hormone (CRH), 10, 131, 137, 184, 190
Computer Tomography (CT), 14
Continuous Performance Test (CPT), 111
Dizygotic twins (DZ), 125, 126, 162
DNA-Deoxyribonucleic acid, 5, 11–14, 41, 48, 50, 51, 65, 66, 68, 73, 80, 107, 109, 112, 115, 136, 137, 143, 196, 197, 199, 200, 205, 213
Dopamine (DA), 4, 24, 27, 32, 33, 36, 48–50, 99, 102, 103, 125, 129, 130, 163, 175, 177, 188, 199, 195, 201–206
Dopamine receptor D2 (DRD2), 24–36, 51, 77, 85, 95, 101, 103, 129, 131, 161, 166, 183, 188
Dopamine receptor D3 (DRD3), 8, 24, 26, 28, 29, 36, 31–33, 35, 36, 49, 128, 129
Dopamine beta hydroxylase gene (DBH), 95, 100, 101, 103, 129
Dopamine transporter 1 (DAT), 10, 51, 95, 99, 100–103
Dopaminergic neurotransmission, 99–102, 163
Dorsolateral Prefrontal Cortex (DLPFC), 77, 82, 84, 86, 95, 107, 167
Drug response, 21, 47, 49, 53, 57, 65–69, 71, 72
Dysbindin (DTNBP1), 8, 9, 95, 99, 100, 109, 114, 115, 128–131

E
Eating disorders, 102, 176
Endophenotype strategy, 135–145, 211, 213

Index

Endoplasmic reticulum (ER), 13, 77, 85
Environment, 3, 51, 88, 99, 108, 125, 126, 151, 166, 168, 169, 173, 175, 176, 179, 183, 189, 197, 199, 200, 202
Epidermal derived growth factor (EDGF), 77, 83, 84
Epigenetic, 5, 11, 51, 90, 115, 126, 144, 152, 153, 173, 179, 213
Epstein Barr virus (EBV), 77, 85, 87, 89
Estradiol, 37
Estrogen, 164, 184, 196, 197
Excitotoxicity, 11
Expressivity, 151, 153
Febrile seizures, 137, 151–155, 157
Fibroblast growth factor (FGF), 77, 82, 84
Focal epilepsy, 151, 155
Functional Magnetic Resonance Imaging (FMRI), 152, 161, 166, 167
Gamma-amino-butyric acid (GABA), 4, 11, 29, 48, 77, 82–84, 129, 177, 189, 190
Gamma-Aminobutyric Acid type A receptor (GABAA), 136, 153, 154
Generalized epilepsy, 135–137, 139, 141, 142, 151–155, 157
Genetic marker, 95, 96, 99, 126, 152, 157, 161–169, 175, 184, 187, 188, 190
Genomic medicine, 3, 13, 14
Genome Wide Association (GWA), 72, 144, 161, 183, 198, 188
Genomics, 5, 13, 14, 20, 21, 48, 72
Glucocorticoid Receptor (GR), 41, 89
Glutamate, 8–10, 33, 50, 77, 83, 84, 100, 105, 106, 130, 156, 173, 175, 177, 202
Glutamatergic neurotransmission, 100, 101, 105
Gray Matter (GM), 88, 104, 143, 186
Hallucinations, 54, 57, 97, 98, 101–104, 111, 115
Hamilton Depression Rating Scale (HDRS), 56
Heritability, 126, 139, 140, 144, 162, 168, 173, 175, 212
Hippocampus, 84, 108, 109, 152, 178, 198, 199, 201, 202, 204
HOPA, 95, 100, 101, 112, 114
Hormone, 10, 50, 105, 131, 137, 184, 190, 195, 196, 198, 199, 213
Hypothalamo-Pituitary-Adrenal axis (HPA axis), 183, 189, 190
Inositol, 4, 10, 36, 48, 127, 129, 130
Imaging genetics, 161–169
Kainic acid, 50
Learning, 12, 48, 102, 151, 178, 195, 198, 210
Lithium (Li), 29, 50, 85, 130
Liquid chromatography, 113
Locus heterogeneity, 151, 153
Magnetic resonance imaging (MRI), 14, 54, 106, 135, 143, 152, 184–186
Magnetic resonance spectroscopy (MRS), 135, 143
Magnetoencephalography (MEG), 152
Major depression, 48, 50, 54, 111, 178, 198, 199, 201, 202
Metabolomics, 14, 21, 90
Methylenetetrahydrofolate reductase (MTHFR), 6, 95, 100, 101, 110, 114, 129–129, 131
Mitochondrial DNA, 5
Monozygotic twins (MZ), 125, 126, 136, 140
Mood disorders, 10, 52–54, 125–133, 184
Movement abnormalities, 213
Multiple sclerosis, 4, 13, 68, 142
Myoclonic epilepsy, 135, 137, 139, 141, 42, 151, 153–155
Nerve growth factor (NGF), 195, 199
Neurochemistry, 211
Neurodegenerative disorder, 6, 11, 51, 199, 205, 206
Neurodevelopment, 108, 154
Neurogenesis, 104
Neuroimaging endophenotypes, 153
Neuron, 5, 12, 13, 18, 50, 51, 70, 85, 86, 89, 113, 130, 151, 54, 156, 178, 179, 186, 188–190, 201–203, 205, 206
Neuropathology, 9, 13
Neuroprotection, 55
Neuropsychiatric disorders, 3, 5, 12, 20, 21, 36, 47, 48, 50, 56, 65, 110, 176, 179, 189, 195, 205, 206
Neuroscience, 189
Nicotinic acetylcholine receptor (nAChR), 156, 187
N-methyl-D-aspartate (NMDA), 53, 95, 100, 105–108, 130, 177, 202
Norepinephrine, 24, 27, 35, 103, 129–131, 163, 165, 177, 178
Nuclear receptor, 41, 112, 188, 195–200, 204–206
Obsessive-Compulsive Disorder (OCD), 9, 10, 105, 162, 173–179
Oligodendrocytes, 77, 78, 82–84, 131, 178, 179
Operational Criteria Checklist of Psychotic Illness (OPCRIT), 95–98, 101, 102, 109, 110
P300, 87
Panic disorder, 54, 161–169
Parkinson’s disease, 4, 5, 10, 13, 20, 50, 68, 143, 163, 195, 199, 203–206
Peripheral markers, 211
Personality, 10, 21, 95, 115, 131, 136, 164, 183–185, 188, 189
Pharmacogenetics, 3, 13, 14, 20–23, 54, 56, 57, 65–73, 116, 125, 131, 132
Pharmacogenomics, 3, 13, 14, 20–22, 47, 48, 51, 56, 57
Phenotypic variation, 98, 103, 138, 213
Photosensitivity, 135, 139, 141
Plasticity, 100, 108, 113, 131, 178, 179, 189
Positive and Negative Syndrome Scale (PANSS), 50, 96, 97, 99, 101–105, 107, 109, 110, 112
Post-traumatic stress disorder (PTSD), 184, 189
Positron emission tomography (PET), 14, 135, 143, 152, 161, 164, 177, 184–186, 206
Potassium conductance calcium-activated channel (hSKCa3/KCNN3), 95, 100, 101, 109, 110, 114
Prefrontal cortex (PFC), 82–85, 108, 111, 167, 168, 184, 188, 202
Protein kinase, 10, 50, 100, 113
Proteomics, 14, 72, 90, 190, 211

R
Regeneration, 100, 113
Retinoic acid, 195, 196, 198, 199
Ribonucleic acid (RNA), 13, 65, 73, 79, 81, 86, 89, 100, 107, 111, 112, 143, 144, 179

S
Selective serotonin reuptake inhibitor (SSRI), 25, 27, 28, 31, 34, 50, 127, 131, 161, 163
Seizures, 69, 70, 135–143, 145, 151–157
Serotonergic neurotransmission, 100–102, 164
Serotonin receptor (5-HT$_2$, and 5-HT$_3$), 36, 95, 100, 105, 131, 177
Scale for the Assessment of Positive (Psychotic) Symptoms (SAPS), 96, 97
Scale for the Assessment of Negative (Psychotic) Symptoms (SANS), 96, 97
Side effects, 20, 53, 57, 99, 190
Single photon emission computed tomography (SPECT), 14, 184–186
Stress, 5, 11–13, 83, 85, 114, 176, 183–185, 189, 190, 199
Striatum, 88, 189, 201–204, 206
Stroke, 5, 55, 57, 152
Suicide, 83, 84
Synapse, 12, 49, 102, 109, 156
Symptom dimensions, 95–116

T
Temporal lobe epilepsy, 137, 139, 151–159
Thalamus, 108, 154
The long serotonin transporter promoter region (5-HTTLPR), 95, 100, 101, 104, 105, 127, 131, 165, 169, 176, 188
Tolerance, 183
Toxicity, 11, 14, 15, 41, 67, 68, 71, 73, 144, 183, 186, 189
Transcranial magnetic stimulation, 151 152, 213
Translin-associated factor X gene (TRAX), 95, 111
Tryptophan, 4, 10, 36, 48, 129, 131, 178

V
Variable number of tandem repeat (VNTR), 49, 68, 95, 102, 103, 129, 176
Vascular dementia, 4, 20
Vitamin A, 196, 198

W
Working Memory, 82, 111